| HYDROXYCHLOROQUINE SULFATE | Small molecule | IGA glomerulonephritis | Toll-like receptor 7 antagonist | 4.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | influenza | Toll-like receptor 7 antagonist | 3.0 | Recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | glioblastoma multiforme | Toll-like receptor 7 antagonist | 2.0 | Completed | ClinicalTrials |
| CPG-52852 | Small molecule | neoplasm | Toll-like receptor 7 agonist | 1.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | antiphospholipid syndrome | Toll-like receptor 7 antagonist | 2.0 | Unknown status | ClinicalTrials |
| HYDROXYCHLOROQUINE SULFATE | Small molecule | rheumatic disease | Toll-like receptor 7 antagonist | 1.0 | Completed | ClinicalTrials |
| VESATOLIMOD | Small molecule | HIV infection | Toll-like receptor 7 activator | 1.0 | Recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | IGA glomerulonephritis | Toll-like receptor 7 antagonist | 4.0 | Unknown status | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | cancer | Toll-like receptor 7 antagonist | 1.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | X-linked Alport syndrome | Toll-like receptor 7 antagonist | 2.0 | Recruiting | ClinicalTrials |
| RESIQUIMOD | Small molecule | oligodendroglioma | Toll-like receptor 7 agonist | 2.0 | Active, not recruiting | ClinicalTrials |
| IMIQUIMOD | Small molecule | actinic keratosis | Toll-like receptor 7 agonist | 4.0 | Unknown status | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | COVID-19 | Toll-like receptor 7 antagonist | 2.0 | Not yet recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | hepatocellular carcinoma | Toll-like receptor 7 antagonist | 2.0 | Recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | pancreatic adenocarcinoma | Toll-like receptor 7 antagonist | 2.0 | Recruiting | ClinicalTrials |
| IMIQUIMOD | Small molecule | cervical carcinoma | Toll-like receptor 7 agonist | 2.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | infection | Toll-like receptor 7 antagonist | 3.0 | Withdrawn | ClinicalTrials |
| HYDROXYCHLOROQUINE SULFATE | Small molecule | malaria | Toll-like receptor 7 antagonist | 4.0 | - | DailyMed |
| HYDROXYCHLOROQUINE | Small molecule | osteoarthritis | Toll-like receptor 7 antagonist | 3.0 | Completed | ClinicalTrials |
| IMIQUIMOD | Small molecule | glioblastoma multiforme | Toll-like receptor 7 agonist | 1.0 | Completed | ClinicalTrials |
| RESIQUIMOD | Small molecule | glioblastoma multiforme | Toll-like receptor 7 agonist | 2.0 | Active, not recruiting | ClinicalTrials |
| IMIQUIMOD | Small molecule | leukemia | Toll-like receptor 7 agonist | 2.0 | Completed | ClinicalTrials |
| IMIQUIMOD | Small molecule | anal neoplasm | Toll-like receptor 7 agonist | 3.0 | Recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | ankylosing spondylitis | Toll-like receptor 7 antagonist | 4.0 | Not yet recruiting | ClinicalTrials |
| IMIQUIMOD | Small molecule | breast cancer | Toll-like receptor 7 agonist | 1.0 | Terminated | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | osteoarthritis, knee | Toll-like receptor 7 antagonist | 2.0 | Completed | ClinicalTrials |
| IMIQUIMOD | Small molecule | localised scleroderma | Toll-like receptor 7 agonist | 3.0 | Withdrawn | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | sarcoma | Toll-like receptor 7 antagonist | 1.0 | Recruiting | ClinicalTrials |
| IMIQUIMOD | Small molecule | mouth neoplasm | Toll-like receptor 7 agonist | 0.5 | Recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | adenocarcinoma | Toll-like receptor 7 antagonist | 1.0 | Completed | ClinicalTrials |
| IMIQUIMOD | Small molecule | anogenital venereal wart | Toll-like receptor 7 agonist | 4.0 | Completed | ClinicalTrials |
| IMIQUIMOD | Small molecule | Cervical Intraepithelial Neoplasia Grade 2/3 | Toll-like receptor 7 agonist | 0.5 | Active, not recruiting | ClinicalTrials |
| ENPATORAN | Small molecule | COVID-19 | Toll-like receptor 7 antagonist | 2.0 | Completed | ClinicalTrials |
| IMIQUIMOD | Small molecule | cutaneous melanoma | Toll-like receptor 7 agonist | 1.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | COVID-19 | Toll-like receptor 7 antagonist | 0.5 | Withdrawn | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | melanoma | Toll-like receptor 7 antagonist | 1.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE SULFATE | Small molecule | COVID-19 | Toll-like receptor 7 antagonist | 2.0 | Not yet recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | Lyme disease | Toll-like receptor 7 antagonist | 4.0 | Completed | ClinicalTrials |
| IMIQUIMOD | Small molecule | hemangioma | Toll-like receptor 7 agonist | 2.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | IGA glomerulonephritis | Toll-like receptor 7 antagonist | 4.0 | Completed | ClinicalTrials |
| AZD-8848 | Small molecule | butyrylcholinesterase deficiency | Toll-like receptor 7 agonist | 1.0 | Completed | ClinicalTrials |
| IMIQUIMOD | Small molecule | acute lymphoblastic leukemia | Toll-like receptor 7 agonist | 1.0 | Active, not recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | HIV infection | Toll-like receptor 7 antagonist | 2.0 | Unknown status | ClinicalTrials |
| HYDROXYCHLOROQUINE SULFATE | Small molecule | pancreatic adenocarcinoma | Toll-like receptor 7 antagonist | 1.0 | Recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | acute respiratory distress syndrome | Toll-like receptor 7 antagonist | 3.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | breast cancer | Toll-like receptor 7 antagonist | 1.0 | Withdrawn | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | viral pneumonia | Toll-like receptor 7 antagonist | 2.0 | Completed | ClinicalTrials |
| IMIQUIMOD | Small molecule | non-melanoma skin carcinoma | Toll-like receptor 7 agonist | 3.0 | Completed | ClinicalTrials |
| RESIQUIMOD | Small molecule | cutaneous melanoma | Toll-like receptor 7 agonist | 0.5 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | melanoma | Toll-like receptor 7 antagonist | 1.0 | Recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | antiphospholipid syndrome | Toll-like receptor 7 antagonist | 3.0 | Terminated | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | viral pneumonia | Toll-like receptor 7 antagonist | 2.0 | Recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | chronic lymphocytic leukemia | Toll-like receptor 7 antagonist | 2.0 | Terminated | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | COVID-19 | Toll-like receptor 7 antagonist | 1.0 | Recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | infection | Toll-like receptor 7 antagonist | 2.0 | Terminated | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | hepatitis C virus infection | Toll-like receptor 7 antagonist | 1.0 | Terminated | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | COVID-19 | Toll-like receptor 7 antagonist | 3.0 | Not yet recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | renal cell carcinoma | Toll-like receptor 7 antagonist | 1.0 | Completed | ClinicalTrials |
| IMIQUIMOD | Small molecule | medulloblastoma | Toll-like receptor 7 agonist | 1.0 | Completed | ClinicalTrials |
| BAZLITORAN | Unknown | diffuse large B-cell lymphoma | Toll-like receptor 7 antagonist | 1.0 | Completed | ClinicalTrials |
| IMIQUIMOD | Small molecule | metastatic malignant neoplasm | Toll-like receptor 7 agonist | 1.0 | Completed | ClinicalTrials |
| IMIQUIMOD | Small molecule | anaplastic astrocytoma | Toll-like receptor 7 agonist | 1.0 | Completed | ClinicalTrials |
| IMIQUIMOD | Small molecule | basal cell carcinoma | Toll-like receptor 7 agonist | 4.0 | - | DailyMed |
| IMIQUIMOD | Small molecule | cheilitis | Toll-like receptor 7 agonist | 1.0 | Terminated | ClinicalTrials |
| IMIQUIMOD | Small molecule | fallopian tube cancer | Toll-like receptor 7 agonist | 2.0 | Active, not recruiting | ClinicalTrials |
| IMIQUIMOD | Small molecule | lentigo maligna melanoma | Toll-like receptor 7 agonist | 3.0 | Active, not recruiting | ClinicalTrials |
| RESIQUIMOD | Small molecule | metastatic melanoma | Toll-like receptor 7 agonist | 1.0 | Unknown status | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | rheumatoid arthritis | Toll-like receptor 7 antagonist | 4.0 | Not yet recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | rheumatoid arthritis | Toll-like receptor 7 antagonist | 4.0 | Recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | pancreatic carcinoma | Toll-like receptor 7 antagonist | 1.0 | Recruiting | ClinicalTrials |
| IMIQUIMOD | Small molecule | familial multiple nevi flammei | Toll-like receptor 7 agonist | 2.0 | Terminated | ClinicalTrials |
| IMIQUIMOD | Small molecule | ovarian cancer | Toll-like receptor 7 agonist | 2.0 | Active, not recruiting | ClinicalTrials |
| IMIQUIMOD | Small molecule | Keloid | Toll-like receptor 7 agonist | 2.0 | Terminated | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | systemic lupus erythematosus | Toll-like receptor 7 antagonist | 2.0 | Active, not recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | pancreatic carcinoma | Toll-like receptor 7 antagonist | 2.0 | Terminated | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | Sjogren syndrome | Toll-like receptor 7 antagonist | 3.0 | Completed | ClinicalTrials |
| GSK-2245035 | Small molecule | asthma | Toll-like receptor 7 agonist | 2.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | COVID-19 | Toll-like receptor 7 antagonist | 3.0 | Withdrawn | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | COVID-19 | Toll-like receptor 7 antagonist | 4.0 | Withdrawn | ClinicalTrials |
| VESATOLIMOD | Small molecule | HIV-1 infection | Toll-like receptor 7 activator | 2.0 | Recruiting | ClinicalTrials |
| IMIQUIMOD | Small molecule | basal cell carcinoma | Toll-like receptor 7 agonist | 4.0 | Completed | ClinicalTrials |
| IMIQUIMOD | Small molecule | cancer | Toll-like receptor 7 agonist | 1.0 | Terminated | ClinicalTrials |
| RESIQUIMOD | Small molecule | neoplasm | Toll-like receptor 7 agonist | 1.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | Central Nervous System Neoplasm | Toll-like receptor 7 antagonist | 1.0 | Completed | ClinicalTrials |
| AZD-8848 | Small molecule | allergic asthma | Toll-like receptor 7 agonist | 2.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | chronic progressive multiple sclerosis | Toll-like receptor 7 antagonist | 2.0 | Recruiting | ClinicalTrials |
| IMIQUIMOD | Small molecule | prostate cancer | Toll-like receptor 7 agonist | 1.0 | Unknown status | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | COVID-19 | Toll-like receptor 7 antagonist | 3.0 | Terminated | ClinicalTrials |
| IMIQUIMOD | Small molecule | breast cancer | Toll-like receptor 7 agonist | 1.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | malignant glioma | Toll-like receptor 7 antagonist | 1.0 | Recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | cutaneous melanoma | Toll-like receptor 7 antagonist | 2.0 | Active, not recruiting | ClinicalTrials |
| CPG-52852 | Small molecule | cutaneous melanoma | Toll-like receptor 7 agonist | 2.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE SULFATE | Small molecule | systemic lupus erythematosus | Toll-like receptor 7 antagonist | 3.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | rheumatic disease | Toll-like receptor 7 antagonist | 1.0 | Completed | ClinicalTrials |
| IMIQUIMOD | Small molecule | squamous cell carcinoma | Toll-like receptor 7 agonist | 1.0 | Recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | coronary artery disease | Toll-like receptor 7 antagonist | 4.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | pancreatic ductal adenocarcinoma | Toll-like receptor 7 antagonist | 0.5 | Recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | preeclampsia | Toll-like receptor 7 antagonist | 3.0 | Not yet recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | rheumatoid arthritis | Toll-like receptor 7 antagonist | 3.0 | Recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | prostate cancer | Toll-like receptor 7 antagonist | 1.0 | Recruiting | ClinicalTrials |
| IMIQUIMOD | Small molecule | ependymoma | Toll-like receptor 7 agonist | 1.0 | Recruiting | ClinicalTrials |
| IMIQUIMOD | Small molecule | invasive carcinoma | Toll-like receptor 7 agonist | 2.0 | Recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | neoplasm | Toll-like receptor 7 antagonist | 1.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | multiple myeloma | Toll-like receptor 7 antagonist | 1.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | pancreatic carcinoma | Toll-like receptor 7 antagonist | 2.0 | Unknown status | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | pneumocystosis | Toll-like receptor 7 antagonist | 3.0 | Completed | ClinicalTrials |
| IMIQUIMOD | Small molecule | cirrhosis of liver | Toll-like receptor 7 agonist | 2.0 | Not yet recruiting | ClinicalTrials |
| IMIQUIMOD | Small molecule | vulvar intraepithelial neoplasia | Toll-like receptor 7 agonist | 3.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | Digestive System Carcinoma | Toll-like receptor 7 antagonist | 1.0 | Active, not recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | Digestive System Carcinoma | Toll-like receptor 7 antagonist | 2.0 | Recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | colorectal carcinoma | Toll-like receptor 7 antagonist | 2.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | COVID-19 | Toll-like receptor 7 antagonist | 2.0 | Active, not recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | rheumatoid arthritis | Toll-like receptor 7 antagonist | 3.0 | Terminated | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | COVID-19 | Toll-like receptor 7 antagonist | 3.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | pancreatic carcinoma | Toll-like receptor 7 antagonist | 2.0 | Not yet recruiting | ClinicalTrials |
| VESATOLIMOD | Small molecule | chronic hepatitis B virus infection | Toll-like receptor 7 activator | 2.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | COVID-19 | Toll-like receptor 7 antagonist | 4.0 | Not yet recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | Sjogren syndrome | Toll-like receptor 7 antagonist | 2.0 | Recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE SULFATE | Small molecule | cholangiocarcinoma | Toll-like receptor 7 antagonist | 2.0 | Completed | ClinicalTrials |
| IMIQUIMOD | Small molecule | influenza | Toll-like receptor 7 agonist | 3.0 | Recruiting | ClinicalTrials |
| IMIQUIMOD | Small molecule | human papilloma virus infection | Toll-like receptor 7 agonist | 1.0 | Terminated | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | pancreatic adenocarcinoma | Toll-like receptor 7 antagonist | 1.0 | Recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | cholangiocarcinoma | Toll-like receptor 7 antagonist | 2.0 | Recruiting | ClinicalTrials |
| IMIQUIMOD | Small molecule | breast cancer | Toll-like receptor 7 agonist | 2.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | interstitial lung disease | Toll-like receptor 7 antagonist | 2.0 | Suspended | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | COVID-19 | Toll-like receptor 7 antagonist | 2.0 | Enrolling by invitation | ClinicalTrials |
| IMIQUIMOD | Small molecule | cervical intraepithelial neoplasia | Toll-like receptor 7 agonist | 3.0 | Unknown status | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | cancer | Toll-like receptor 7 antagonist | 2.0 | Recruiting | ClinicalTrials |
| IMIQUIMOD | Small molecule | actinic keratosis | Toll-like receptor 7 agonist | 1.0 | Completed | ClinicalTrials |
| IMIQUIMOD | Small molecule | actinic keratosis | Toll-like receptor 7 agonist | 2.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | non-small cell lung carcinoma | Toll-like receptor 7 antagonist | 1.0 | Unknown status | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | cystic fibrosis | Toll-like receptor 7 antagonist | 1.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | ulcerative colitis | Toll-like receptor 7 antagonist | 1.0 | Recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | COVID-19 | Toll-like receptor 7 antagonist | 2.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | renal cell carcinoma | Toll-like receptor 7 antagonist | 1.0 | Terminated | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | low grade glioma | Toll-like receptor 7 antagonist | 1.0 | Recruiting | ClinicalTrials |
| IMIQUIMOD | Small molecule | Cervical Intraepithelial Neoplasia Grade 2/3 | Toll-like receptor 7 agonist | 1.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE SULFATE | Small molecule | lung disease | Toll-like receptor 7 antagonist | 3.0 | Withdrawn | ClinicalTrials |
| IMIQUIMOD | Small molecule | anogenital venereal wart | Toll-like receptor 7 agonist | 3.0 | Not yet recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | malaria | Toll-like receptor 7 antagonist | 4.0 | - | ATC,DailyMed |
| HYDROXYCHLOROQUINE SULFATE | Small molecule | cutaneous lupus erythematosus | Toll-like receptor 7 antagonist | 3.0 | Completed | ClinicalTrials |
| BAZLITORAN | Unknown | dermatomyositis | Toll-like receptor 7 antagonist | 2.0 | Completed | ClinicalTrials |
| GSK-2245035 | Small molecule | asthma | Toll-like receptor 7 agonist | 2.0 | Withdrawn | ClinicalTrials |
| HYDROXYCHLOROQUINE SULFATE | Small molecule | rheumatoid arthritis | Toll-like receptor 7 antagonist | 4.0 | - | DailyMed |
| HYDROXYCHLOROQUINE | Small molecule | cholangiocarcinoma | Toll-like receptor 7 antagonist | 2.0 | Completed | ClinicalTrials |
| VESATOLIMOD | Small molecule | hepatitis B virus infection | Toll-like receptor 7 activator | 1.0 | Completed | ClinicalTrials |
| AZD-8848 | Small molecule | allergic rhinitis | Toll-like receptor 7 agonist | 1.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | rheumatoid arthritis | Toll-like receptor 7 antagonist | 3.0 | Completed | ClinicalTrials |
| IMIQUIMOD | Small molecule | actinic keratosis | Toll-like receptor 7 agonist | 3.0 | Completed | ClinicalTrials |
| IMIQUIMOD | Small molecule | prostate adenocarcinoma | Toll-like receptor 7 agonist | 1.0 | Completed | ClinicalTrials |
| IMIQUIMOD | Small molecule | plantar wart | Toll-like receptor 7 agonist | 4.0 | Terminated | ClinicalTrials |
| CPG-52852 | Small molecule | melanoma | Toll-like receptor 7 agonist | 1.0 | Completed | ClinicalTrials |
| IMIQUIMOD | Small molecule | lentigo | Toll-like receptor 7 agonist | 2.0 | Unknown status | ClinicalTrials |
| IMIQUIMOD | Small molecule | chronic lymphocytic leukemia | Toll-like receptor 7 agonist | 2.0 | Terminated | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | cutaneous melanoma | Toll-like receptor 7 antagonist | 0.5 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | COVID-19 | Toll-like receptor 7 antagonist | 1.0 | Terminated | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | COVID-19 | Toll-like receptor 7 antagonist | 4.0 | Enrolling by invitation | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | COVID-19 | Toll-like receptor 7 antagonist | 4.0 | Suspended | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | clear cell renal carcinoma | Toll-like receptor 7 antagonist | 1.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | rheumatoid arthritis | Toll-like receptor 7 antagonist | 4.0 | - | DailyMed |
| HYDROXYCHLOROQUINE | Small molecule | breast cancer | Toll-like receptor 7 antagonist | 1.0 | Terminated | ClinicalTrials |
| BAZLITORAN | Unknown | psoriasis | Toll-like receptor 7 antagonist | 2.0 | Completed | ClinicalTrials |
| IMIQUIMOD | Small molecule | non-small cell lung carcinoma | Toll-like receptor 7 agonist | 2.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | chronic hepatitis C virus infection | Toll-like receptor 7 antagonist | 1.0 | Unknown status | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | non-small cell lung carcinoma | Toll-like receptor 7 antagonist | 2.0 | Unknown status | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | COVID-19 | Toll-like receptor 7 antagonist | 2.0 | Terminated | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | respiratory failure | Toll-like receptor 7 antagonist | 3.0 | Terminated | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | pneumonia | Toll-like receptor 7 antagonist | 3.0 | Recruiting | ClinicalTrials |
| RESIQUIMOD | Small molecule | cancer | Toll-like receptor 7 agonist | 1.0 | Completed | ClinicalTrials |
| IMIQUIMOD | Small molecule | melanoma | Toll-like receptor 7 agonist | 1.0 | Completed | ClinicalTrials |
| IMIQUIMOD | Small molecule | influenza | Toll-like receptor 7 agonist | 3.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE SULFATE | Small molecule | Sjogren syndrome | Toll-like receptor 7 antagonist | 4.0 | Recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | pneumonia | Toll-like receptor 7 antagonist | 3.0 | Not yet recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | respiratory failure | Toll-like receptor 7 antagonist | 2.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | severe acute respiratory syndrome | Toll-like receptor 7 antagonist | 3.0 | Terminated | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | malaria | Toll-like receptor 7 antagonist | 0.5 | Enrolling by invitation | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | antiphospholipid syndrome | Toll-like receptor 7 antagonist | 2.0 | Recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | severe acute respiratory syndrome | Toll-like receptor 7 antagonist | 2.0 | Not yet recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | COVID-19 | Toll-like receptor 7 antagonist | 1.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | non-small cell lung carcinoma | Toll-like receptor 7 antagonist | 1.0 | Terminated | ClinicalTrials |
| IMIQUIMOD | Small molecule | keratosis | Toll-like receptor 7 agonist | 4.0 | - | DailyMed |
| HYDROXYCHLOROQUINE | Small molecule | COVID-19 | Toll-like receptor 7 antagonist | 1.0 | Withdrawn | ClinicalTrials |
| HYDROXYCHLOROQUINE SULFATE | Small molecule | COVID-19 | Toll-like receptor 7 antagonist | 1.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | HIV infection | Toll-like receptor 7 antagonist | 1.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | non-small cell lung carcinoma | Toll-like receptor 7 antagonist | 1.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | systemic lupus erythematosus | Toll-like receptor 7 antagonist | 3.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | lung cancer | Toll-like receptor 7 antagonist | 1.0 | Terminated | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | pregnancy | Toll-like receptor 7 antagonist | 2.0 | Withdrawn | ClinicalTrials |
| BAZLITORAN | Unknown | Waldenstrom macroglobulinemia | Toll-like receptor 7 antagonist | 1.0 | Terminated | ClinicalTrials |
| IMIQUIMOD | Small molecule | keratosis | Toll-like receptor 7 agonist | 4.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | acute respiratory distress syndrome | Toll-like receptor 7 antagonist | 1.0 | Recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | lymphangioleiomyomatosis | Toll-like receptor 7 antagonist | 1.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | prostate carcinoma | Toll-like receptor 7 antagonist | 0.5 | Terminated | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | ovarian cancer | Toll-like receptor 7 antagonist | 1.0 | Completed | ClinicalTrials |
| IMIQUIMOD | Small molecule | viral disease | Toll-like receptor 7 agonist | 4.0 | - | ATC |
| ENPATORAN | Small molecule | cutaneous lupus erythematosus | Toll-like receptor 7 antagonist | 1.0 | Recruiting | ClinicalTrials |
| IMIQUIMOD | Small molecule | anogenital venereal wart | Toll-like receptor 7 agonist | 2.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | Thrombocytopenia | Toll-like receptor 7 antagonist | 3.0 | Terminated | ClinicalTrials |
| HYDROXYCHLOROQUINE SULFATE | Small molecule | COVID-19 | Toll-like receptor 7 antagonist | 0.5 | Suspended | ClinicalTrials |
| IMIQUIMOD | Small molecule | actinic keratosis | Toll-like receptor 7 agonist | 4.0 | - | DailyMed |
| HYDROXYCHLOROQUINE | Small molecule | coronavirus infectious disease | Toll-like receptor 7 antagonist | 3.0 | Terminated | ClinicalTrials |
| IMIQUIMOD | Small molecule | grade II glioma | Toll-like receptor 7 agonist | 0.5 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | coronavirus infectious disease | Toll-like receptor 7 antagonist | 3.0 | Withdrawn | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | chronic progressive multiple sclerosis | Toll-like receptor 7 antagonist | 2.0 | Completed | ClinicalTrials |
| IMIQUIMOD | Small molecule | cheilitis | Toll-like receptor 7 agonist | 4.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE SULFATE | Small molecule | obesity | Toll-like receptor 7 antagonist | 4.0 | Not yet recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | alopecia areata | Toll-like receptor 7 antagonist | 4.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE SULFATE | Small molecule | COVID-19 | Toll-like receptor 7 antagonist | 2.0 | Terminated | ClinicalTrials |
| HYDROXYCHLOROQUINE SULFATE | Small molecule | antiphospholipid syndrome | Toll-like receptor 7 antagonist | 2.0 | Recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | pulmonary sarcoidosis | Toll-like receptor 7 antagonist | 3.0 | Not yet recruiting | ClinicalTrials |
| IMIQUIMOD | Small molecule | kidney failure | Toll-like receptor 7 agonist | 2.0 | Completed | ClinicalTrials |
| IMIQUIMOD | Small molecule | diffuse intrinsic pontine glioma | Toll-like receptor 7 agonist | 1.0 | Terminated | ClinicalTrials |
| ENPATORAN | Small molecule | systemic lupus erythematosus | Toll-like receptor 7 antagonist | 2.0 | Recruiting | ClinicalTrials |
| IMIQUIMOD | Small molecule | avian influenza | Toll-like receptor 7 agonist | 1.0 | Completed | ClinicalTrials |
| IMIQUIMOD | Small molecule | lentigo | Toll-like receptor 7 agonist | 3.0 | Active, not recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | sarcoma | Toll-like receptor 7 antagonist | 2.0 | Terminated | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | multiple myeloma | Toll-like receptor 7 antagonist | 0.5 | Completed | ClinicalTrials |
| RESIQUIMOD | Small molecule | Cutaneous T-cell lymphoma | Toll-like receptor 7 agonist | 1.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | COVID-19 | Toll-like receptor 7 antagonist | 4.0 | Completed | ClinicalTrials |
| IMIQUIMOD | Small molecule | bone sarcoma | Toll-like receptor 7 agonist | 1.0 | Active, not recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | HIV infection | Toll-like receptor 7 antagonist | 1.0 | Unknown status | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | lichen planus | Toll-like receptor 7 antagonist | 2.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | Graves ophthalmopathy | Toll-like receptor 7 antagonist | 4.0 | Recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | COVID-19 | Toll-like receptor 7 antagonist | 4.0 | Terminated | ClinicalTrials |
| HYDROXYCHLOROQUINE SULFATE | Small molecule | COVID-19 | Toll-like receptor 7 antagonist | 2.0 | Active, not recruiting | ClinicalTrials |
| IMIQUIMOD | Small molecule | glioblastoma multiforme | Toll-like receptor 7 agonist | 1.0 | Terminated | ClinicalTrials |
| IMIQUIMOD | Small molecule | basal cell carcinoma | Toll-like receptor 7 agonist | 3.0 | Not yet recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | breast cancer | Toll-like receptor 7 antagonist | 1.0 | Suspended | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | neoplasm | Toll-like receptor 7 antagonist | 1.0 | Recruiting | ClinicalTrials |
| IMIQUIMOD | Small molecule | primary peritoneal carcinoma | Toll-like receptor 7 agonist | 2.0 | Active, not recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | interstitial lung disease | Toll-like receptor 7 antagonist | 0.5 | Not yet recruiting | ClinicalTrials |
| VESATOLIMOD | Small molecule | HIV-1 infection | Toll-like receptor 7 activator | 1.0 | Completed | ClinicalTrials |
| IMIQUIMOD | Small molecule | alopecia areata | Toll-like receptor 7 agonist | 4.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | habitual abortion | Toll-like receptor 7 antagonist | 3.0 | Recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | type 2 diabetes mellitus | Toll-like receptor 7 antagonist | 1.0 | Unknown status | ClinicalTrials |
| IMIQUIMOD | Small molecule | localised scleroderma | Toll-like receptor 7 agonist | 3.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | severe acute respiratory syndrome | Toll-like receptor 7 antagonist | 2.0 | Terminated | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | COVID-19 | Toll-like receptor 7 antagonist | 0.5 | Suspended | ClinicalTrials |
| IMIQUIMOD | Small molecule | hepatitis B virus infection | Toll-like receptor 7 agonist | 2.0 | Not yet recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | prostate cancer | Toll-like receptor 7 antagonist | 2.0 | Terminated | ClinicalTrials |
| IMIQUIMOD | Small molecule | actinic keratosis | Toll-like receptor 7 agonist | 4.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | Mastocytosis | Toll-like receptor 7 antagonist | 2.0 | Not yet recruiting | ClinicalTrials |
| RESIQUIMOD | Small molecule | mucosal melanoma | Toll-like receptor 7 agonist | 1.0 | Unknown status | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | breast cancer | Toll-like receptor 7 antagonist | 1.0 | Active, not recruiting | ClinicalTrials |
| RESIQUIMOD | Small molecule | Cutaneous T-cell lymphoma | Toll-like receptor 7 agonist | 2.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | systemic lupus erythematosus | Toll-like receptor 7 antagonist | 4.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | rheumatoid arthritis | Toll-like receptor 7 antagonist | 2.0 | Active, not recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | COVID-19 | Toll-like receptor 7 antagonist | 2.0 | Recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE SULFATE | Small molecule | rheumatoid arthritis | Toll-like receptor 7 antagonist | 4.0 | Completed | ClinicalTrials |
| RESIQUIMOD | Small molecule | actinic keratosis | Toll-like receptor 7 agonist | 2.0 | Completed | ClinicalTrials |
| IMIQUIMOD | Small molecule | lentigo | Toll-like receptor 7 agonist | 4.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | insulin resistance | Toll-like receptor 7 antagonist | 1.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | breast cancer | Toll-like receptor 7 antagonist | 2.0 | Recruiting | ClinicalTrials |
| RESIQUIMOD | Small molecule | melanoma | Toll-like receptor 7 agonist | 0.5 | Completed | ClinicalTrials |
| IMIQUIMOD | Small molecule | skin basal cell carcinoma | Toll-like receptor 7 agonist | 2.0 | Recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE SULFATE | Small molecule | COVID-19 | Toll-like receptor 7 antagonist | 3.0 | Withdrawn | ClinicalTrials |
| HYDROXYCHLOROQUINE SULFATE | Small molecule | COVID-19 | Toll-like receptor 7 antagonist | 4.0 | Terminated | ClinicalTrials |
| IMIQUIMOD | Small molecule | Extramammary Paget Disease | Toll-like receptor 7 agonist | 3.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | COVID-19 | Toll-like receptor 7 antagonist | 2.0 | Withdrawn | ClinicalTrials |
| IMIQUIMOD | Small molecule | skin disease | Toll-like receptor 7 agonist | 4.0 | Recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | cutaneous lupus erythematosus | Toll-like receptor 7 antagonist | 4.0 | Completed | ClinicalTrials |
| IMIQUIMOD | Small molecule | basal cell carcinoma | Toll-like receptor 7 agonist | 4.0 | Unknown status | ClinicalTrials |
| IMIQUIMOD | Small molecule | cutaneous Leishmaniasis | Toll-like receptor 7 agonist | 2.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | cutaneous lupus erythematosus | Toll-like receptor 7 antagonist | 3.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | temporal arteritis | Toll-like receptor 7 antagonist | 3.0 | Completed | ClinicalTrials |
| VESATOLIMOD | Small molecule | AIDS | Toll-like receptor 7 activator | 2.0 | Active, not recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE SULFATE | Small molecule | coronary artery disease | Toll-like receptor 7 antagonist | 4.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | myelodysplastic syndrome | Toll-like receptor 7 antagonist | 1.0 | Withdrawn | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | type 2 diabetes mellitus | Toll-like receptor 7 antagonist | 2.0 | Terminated | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | infection | Toll-like receptor 7 antagonist | 3.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE SULFATE | Small molecule | coronavirus infectious disease | Toll-like receptor 7 antagonist | 3.0 | Withdrawn | ClinicalTrials |
| HYDROXYCHLOROQUINE SULFATE | Small molecule | COVID-19 | Toll-like receptor 7 antagonist | 2.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | Zellweger syndrome | Toll-like receptor 7 antagonist | 2.0 | Completed | ClinicalTrials |
| RESIQUIMOD | Small molecule | anaplastic astrocytoma | Toll-like receptor 7 agonist | 2.0 | Active, not recruiting | ClinicalTrials |
| IMIQUIMOD | Small molecule | cervical intraepithelial neoplasia | Toll-like receptor 7 agonist | 2.0 | Active, not recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | rheumatoid arthritis | Toll-like receptor 7 antagonist | 4.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE SULFATE | Small molecule | malaria | Toll-like receptor 7 antagonist | 0.5 | Enrolling by invitation | ClinicalTrials |
| RESIQUIMOD | Small molecule | influenza | Toll-like receptor 7 agonist | 1.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | non-small cell lung carcinoma | Toll-like receptor 7 antagonist | 2.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE SULFATE | Small molecule | systemic lupus erythematosus | Toll-like receptor 7 antagonist | 2.0 | Terminated | ClinicalTrials |
| HYDROXYCHLOROQUINE SULFATE | Small molecule | COVID-19 | Toll-like receptor 7 antagonist | 3.0 | Terminated | ClinicalTrials |
| IMIQUIMOD | Small molecule | influenza | Toll-like receptor 7 agonist | 2.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | COVID-19 | Toll-like receptor 7 antagonist | 4.0 | Recruiting | ClinicalTrials |
| IMIQUIMOD | Small molecule | malignant glioma | Toll-like receptor 7 agonist | 1.0 | Completed | ClinicalTrials |
| IMIQUIMOD | Small molecule | ependymoma | Toll-like receptor 7 agonist | 1.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | osteosarcoma | Toll-like receptor 7 antagonist | 1.0 | Recruiting | ClinicalTrials |
| IMIQUIMOD | Small molecule | human papilloma virus infection | Toll-like receptor 7 agonist | 2.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | acute myeloid leukemia | Toll-like receptor 7 antagonist | 1.0 | Terminated | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | neoplasm | Toll-like receptor 7 antagonist | 1.0 | Active, not recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | Sjogren syndrome | Toll-like receptor 7 antagonist | 4.0 | Recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | viral pneumonia | Toll-like receptor 7 antagonist | 3.0 | Completed | ClinicalTrials |
| IMIQUIMOD | Small molecule | soft tissue sarcoma | Toll-like receptor 7 agonist | 1.0 | Active, not recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | colorectal neoplasm | Toll-like receptor 7 antagonist | 1.0 | Recruiting | ClinicalTrials |
| IMIQUIMOD | Small molecule | basal cell carcinoma | Toll-like receptor 7 agonist | 3.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | colorectal carcinoma | Toll-like receptor 7 antagonist | 1.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | graft versus host disease | Toll-like receptor 7 antagonist | 3.0 | Completed | ClinicalTrials |
| IMIQUIMOD | Small molecule | melanoma | Toll-like receptor 7 agonist | 2.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | hidradenitis suppurativa | Toll-like receptor 7 antagonist | 1.0 | Completed | ClinicalTrials |
| IMIQUIMOD | Small molecule | cervical cancer | Toll-like receptor 7 agonist | 2.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | severe acute respiratory syndrome | Toll-like receptor 7 antagonist | 2.0 | Recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | non-small cell lung carcinoma | Toll-like receptor 7 antagonist | 2.0 | Recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | coronavirus infectious disease | Toll-like receptor 7 antagonist | 3.0 | Completed | ClinicalTrials |
| IMIQUIMOD | Small molecule | cervical intraepithelial neoplasia | Toll-like receptor 7 agonist | 2.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | neoplasm | Toll-like receptor 7 antagonist | 1.0 | Terminated | ClinicalTrials |
| HYDROXYCHLOROQUINE SULFATE | Small molecule | pancreatic carcinoma | Toll-like receptor 7 antagonist | 2.0 | Recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE SULFATE | Small molecule | COVID-19 | Toll-like receptor 7 antagonist | 4.0 | Active, not recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | pregnancy | Toll-like receptor 7 antagonist | 1.0 | Not yet recruiting | ClinicalTrials |
| VESATOLIMOD | Small molecule | hepatitis C virus infection | Toll-like receptor 7 activator | 1.0 | Completed | ClinicalTrials |
| IMIQUIMOD | Small molecule | Cutaneous T-cell lymphoma | Toll-like receptor 7 agonist | 0.5 | Unknown status | ClinicalTrials |
| IMIQUIMOD | Small molecule | squamous cell intraepithelial neoplasia | Toll-like receptor 7 agonist | 3.0 | Recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | COVID-19 | Toll-like receptor 7 antagonist | 2.0 | Suspended | ClinicalTrials |
| HYDROXYCHLOROQUINE SULFATE | Small molecule | COVID-19 | Toll-like receptor 7 antagonist | 2.0 | Withdrawn | ClinicalTrials |
| HYDROXYCHLOROQUINE SULFATE | Small molecule | cutaneous melanoma | Toll-like receptor 7 antagonist | 2.0 | Active, not recruiting | ClinicalTrials |
| IMIQUIMOD | Small molecule | actinic keratosis | Toll-like receptor 7 agonist | 4.0 | Terminated | ClinicalTrials |
| HYDROXYCHLOROQUINE SULFATE | Small molecule | IGA glomerulonephritis | Toll-like receptor 7 antagonist | 4.0 | Unknown status | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | autoimmune thrombocytopenic purpura | Toll-like receptor 7 antagonist | 4.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | prostate cancer | Toll-like receptor 7 antagonist | 2.0 | Completed | ClinicalTrials |
| IMIQUIMOD | Small molecule | central nervous system cancer | Toll-like receptor 7 agonist | 1.0 | Not yet recruiting | ClinicalTrials |
| AZD-8848 | Small molecule | allergic rhinitis | Toll-like receptor 7 agonist | 2.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | COVID-19 | Toll-like receptor 7 antagonist | 3.0 | Active, not recruiting | ClinicalTrials |
| IMIQUIMOD | Small molecule | anogenital venereal wart | Toll-like receptor 7 agonist | 3.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | adult acute respiratory distress syndrome | Toll-like receptor 7 antagonist | 3.0 | Terminated | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | obesity | Toll-like receptor 7 antagonist | 4.0 | Not yet recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | pancreatic carcinoma | Toll-like receptor 7 antagonist | 2.0 | Completed | ClinicalTrials |
| IMIQUIMOD | Small molecule | hepatitis B virus infection | Toll-like receptor 7 agonist | 2.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | retinitis pigmentosa | Toll-like receptor 7 antagonist | 1.0 | Recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | COVID-19 | Toll-like receptor 7 antagonist | 3.0 | Recruiting | ClinicalTrials |
| RESIQUIMOD | Small molecule | melanoma | Toll-like receptor 7 agonist | 2.0 | Completed | ClinicalTrials |
| RESIQUIMOD | Small molecule | basal cell carcinoma | Toll-like receptor 7 agonist | 1.0 | Terminated | ClinicalTrials |
| TELRATOLIMOD | Small molecule | Cutaneous T-cell lymphoma | Toll-like receptor 7 agonist | 1.0 | Terminated | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | lung disease | Toll-like receptor 7 antagonist | 3.0 | Withdrawn | ClinicalTrials |
| IMIQUIMOD | Small molecule | cutaneous Leishmaniasis | Toll-like receptor 7 agonist | 3.0 | Completed | ClinicalTrials |
| IMIQUIMOD | Small molecule | non-melanoma skin carcinoma | Toll-like receptor 7 agonist | 1.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE SULFATE | Small molecule | COVID-19 | Toll-like receptor 7 antagonist | 3.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE SULFATE | Small molecule | X-linked Alport syndrome | Toll-like receptor 7 antagonist | 2.0 | Recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | antiphospholipid syndrome | Toll-like receptor 7 antagonist | 3.0 | Not yet recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | viral pneumonia | Toll-like receptor 7 antagonist | 2.0 | Terminated | ClinicalTrials |
| IMIQUIMOD | Small molecule | colorectal carcinoma | Toll-like receptor 7 agonist | 1.0 | Completed | ClinicalTrials |
| IMIQUIMOD | Small molecule | brain cancer | Toll-like receptor 7 agonist | 1.0 | Terminated | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | systemic lupus erythematosus | Toll-like receptor 7 antagonist | 2.0 | Terminated | ClinicalTrials |
| TELRATOLIMOD | Small molecule | HIV infection | Toll-like receptor 7 agonist | 1.0 | Recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | pregnancy | Toll-like receptor 7 antagonist | 3.0 | Recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | porphyria cutanea tarda | Toll-like receptor 7 antagonist | 2.0 | Unknown status | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | acute respiratory distress syndrome | Toll-like receptor 7 antagonist | 2.0 | Recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | colorectal carcinoma | Toll-like receptor 7 antagonist | 2.0 | Recruiting | ClinicalTrials |
| IMIQUIMOD | Small molecule | intraepithelial neoplasia | Toll-like receptor 7 agonist | 2.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | small cell lung carcinoma | Toll-like receptor 7 antagonist | 2.0 | Terminated | ClinicalTrials |
| IMIQUIMOD | Small molecule | cervical intraepithelial neoplasia | Toll-like receptor 7 agonist | 3.0 | Terminated | ClinicalTrials |
| RESIQUIMOD | Small molecule | hepatitis B virus infection | Toll-like receptor 7 agonist | 1.0 | Completed | ClinicalTrials |
| IMIQUIMOD | Small molecule | Plasmodium falciparum malaria | Toll-like receptor 7 agonist | 0.5 | Not yet recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | leukemia | Toll-like receptor 7 antagonist | 2.0 | Unknown status | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | rheumatoid arthritis | Toll-like receptor 7 antagonist | 4.0 | Active, not recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE SULFATE | Small molecule | interstitial lung disease | Toll-like receptor 7 antagonist | 2.0 | Suspended | ClinicalTrials |
| IMIQUIMOD | Small molecule | cervical squamous cell carcinoma | Toll-like receptor 7 agonist | 0.5 | Active, not recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | pulmonary sarcoidosis | Toll-like receptor 7 antagonist | 3.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | Crohn's disease | Toll-like receptor 7 antagonist | 2.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | severe acute respiratory syndrome | Toll-like receptor 7 antagonist | 3.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | pancreatic carcinoma | Toll-like receptor 7 antagonist | 1.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | prediabetes syndrome | Toll-like receptor 7 antagonist | 4.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | type 1 diabetes mellitus | Toll-like receptor 7 antagonist | 2.0 | Active, not recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | pancreatic carcinoma | Toll-like receptor 7 antagonist | 2.0 | Recruiting | ClinicalTrials |
| IMIQUIMOD | Small molecule | basal cell carcinoma | Toll-like receptor 7 agonist | 3.0 | Active, not recruiting | ClinicalTrials |
| BAZLITORAN | Unknown | Waldenstrom macroglobulinemia | Toll-like receptor 7 antagonist | 1.0 | Completed | ClinicalTrials |
| GSK-2245035 | Small molecule | atopic asthma | Toll-like receptor 7 agonist | 2.0 | Completed | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | pancreatic adenocarcinoma | Toll-like receptor 7 antagonist | 1.0 | Active, not recruiting | ClinicalTrials |
| ENPATORAN | Small molecule | systemic lupus erythematosus | Toll-like receptor 7 antagonist | 1.0 | Recruiting | ClinicalTrials |
| HYDROXYCHLOROQUINE | Small molecule | COVID-19 | Toll-like receptor 7 antagonist | 4.0 | Active, not recruiting | ClinicalTrials |